Holen Sie sich die Stockscreener-App
45.99
2.40%
-1.13
Handel nachbörslich:
45.99
Schlusskurs vom Vortag:
$47.12
Offen:
$47.35
24-Stunden-Volumen:
324.24K
Relative Volume:
1.07
Marktkapitalisierung:
$2.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-80.77M
KGV:
-36.21
EPS:
-1.27
Netto-Cashflow:
$-80.80M
1W Leistung:
+0.63%
1M Leistung:
-15.07%
6M Leistung:
+10.42%
1J Leistung:
-17.70%
1-Tages-Spanne:
$45.26
$47.35
1-Wochen-Bereich:
$44.02
$47.72
52-Wochen-Spanne:
$37.55
$64.98
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
45.99 | 2.90B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Swiss company MoonLake leverages Cambridge in transformative year - Business Weekly
When the Price of (MLTX) Talks, People Listen - Stock Traders Daily
Cantor Fitzgerald Estimates MLTX FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on MLTX FY2025 Earnings - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 6.3%Still a Buy? - MarketBeat
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpWhat's Next? - MarketBeat
MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN
This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat
MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat
MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks
MLTX Crosses Below Key Moving Average Level - Nasdaq
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Yahoo Finance
MoonLake initiates three new clinical trials and further - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Finansavisen
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Barclays PLC Acquires 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Raised by State Street Corp - Defense World
State Street Corp Increases Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 5.1%Time to Buy? - MarketBeat
When (MLTX) Moves Investors should Listen - Stock Traders Daily
Moonlake Immunotherapeutics Announces Resignation of Kara Lassen as Board Member, Effective December 31, 2024 - Marketscreener.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3.2%Here's Why - MarketBeat
MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com
MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks
MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St
Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):